Ghrelin Sex- and Cycle-Related Differences: Normal Range, Optimal Levels, and What Your Results Mean

What Is Ghrelin and Why Does Biological Sex Change It?

Ghrelin is a 28-amino-acid peptide produced mainly by X/A-like cells in the gastric oxyntic mucosa. It drives hunger, promotes fat storage, and stimulates growth-hormone release via the growth-hormone secretagogue receptor 1a (GHSR-1a). Two circulating forms exist: acyl ghrelin (the active, appetite-stimulating form, roughly 10 to 20% of total) and des-acyl (unacylated) ghrelin, which may have metabolic actions of its own. Most commercial assays measure total ghrelin unless specifically ordered as acyl.

Sex hormones modulate ghrelin directly. Estradiol suppresses ghrelin secretion at the hypothalamic and gastric level, while testosterone exerts a similar but weaker suppressive effect. Because women cycle through wide estradiol ranges each month and men carry steadier (though individually variable) testosterone, the downstream ghrelin pattern differs in both mean level and temporal shape.

Why Women Have Higher Average Ghrelin

Population data published in the Journal of Clinical Endocrinology and Metabolism show fasting total ghrelin running 20 to 30% higher in premenopausal women than in age- and BMI-matched men. [1] The difference is not fully explained by body-fat percentage alone. Ovarian estradiol suppresses ghrelin at the level of gastric X/A-like cells, but progesterone appears to attenuate that suppression, producing a net effect that changes week to week.

The Testosterone Connection in Men

A 2003 study by Pagotto et al. (N=45) found that men with hypogonadism (total testosterone <300 ng/dL) had fasting acyl ghrelin roughly 40% higher than eugonadal controls matched for age and BMI. [2] Testosterone-replacement therapy brought ghrelin back toward normal range over 12 weeks, suggesting the relationship is pharmacologically modifiable. This matters clinically: a man presenting with appetite dysregulation or weight-loss resistance should have both ghrelin and a full testosterone panel reviewed together, not in isolation.

Ghrelin Across the Menstrual Cycle

Ghrelin does not stay flat across a 28-day cycle. It follows a pattern that mirrors the inverse of estradiol, dropping to its lowest point around days 12 to 14 and climbing again during the luteal phase as progesterone rises and estradiol falls.

Follicular Phase (Days 1 to 13)

Fasting ghrelin is relatively elevated early in the follicular phase when both estradiol and progesterone are low. A study by Kluge et al. Measuring serial ghrelin samples across the cycle in 17 healthy women found follicular-phase fasting ghrelin approximately 15% higher than the mid-cycle nadir. [3] Appetite scores tracked in parallel, which may partly explain the well-documented increase in caloric intake during the early follicular phase.

Periovulatory Phase (Days 12 to 16)

The periovulatory estradiol surge is the strongest suppressive signal ghrelin encounters across the cycle. Ghrelin hits its monthly nadir here. Some women report the lowest subjective hunger of their cycle in these days, consistent with both ghrelin suppression and the known anorectic effect of peak estradiol. [3]

Luteal Phase (Days 15 to 28)

Ghrelin rises again as estradiol falls and progesterone peaks. Caloric intake in the luteal phase may exceed follicular-phase intake by 90 to 500 kcal/day in controlled feeding studies, and ghrelin's rebound is one plausible mechanism, though cravings and hedonic eating are also progesterone-mediated. [4]

Clinicians measuring ghrelin in women for clinical decision-making should document cycle day at the time of draw. A result of 95 pg/mL (acyl) in the luteal phase carries a different meaning than the same number drawn at ovulation.

Ghrelin in Perimenopause and Postmenopause

Menopause removes the monthly estradiol surge that repeatedly suppresses ghrelin. Postmenopausal women show fasting ghrelin levels closer to those of men than to premenopausal women, though absolute comparisons are complicated by the simultaneous rise in BMI that accompanies menopause transition (and BMI inversely correlates with ghrelin). [5]

Hormone-Therapy Effects on Ghrelin

Oral estradiol-containing hormone therapy modestly suppresses fasting ghrelin in postmenopausal women. A 2004 crossover trial (N=30) in Menopause found that women on combined oral estrogen-progestogen had fasting total ghrelin 12% lower than women on placebo at 12 weeks. [5] Transdermal estradiol produced a smaller, non-statistically significant reduction, possibly because transdermal delivery avoids hepatic first-pass effects that may amplify estrogenic ghrelin suppression.

Clinical Takeaway for Menopausal Patients

A postmenopausal patient with elevated ghrelin who complains of persistent hunger despite adequate caloric intake should be evaluated for both hormonal and metabolic drivers. Checking fasting acyl ghrelin alongside estradiol, FSH, and fasting insulin gives the full picture.

Ghrelin Normal Range: What Labs Report vs. What Is Optimal

Reference ranges vary by assay, sample type, and whether the lab measures total or acyl ghrelin. These numbers represent the most widely cited ranges from peer-reviewed validation studies.

Reported Reference Ranges

| Form | Population | Fasting Reference Range | |---|---|---| | Acyl ghrelin | Healthy adults | 10 to 115 pg/mL | | Total ghrelin | Healthy adults | 300 to 1,000 pg/mL | | Acyl ghrelin | Obese adults | 5 to 60 pg/mL (lower due to BMI) | | Total ghrelin | Postmenopausal women | 250 to 850 pg/mL |

These ranges originate from assay-validation papers and normative cohort data, including work by Hosoda et al. Who developed and validated the first specific acyl-ghrelin ELISA. [6]

What "Optimal" Means in a Longevity Context

A strict normal-range interpretation says nothing about long-term metabolic risk. Persistently high fasting ghrelin (acyl ghrelin above 70 to 80 pg/mL in a fasting, non-obese adult) has been associated with greater weight regain after diet-induced weight loss in the CALERIE trial ancillary data and in a 2011 paper by Sumithran et al. (N=50) in the New England Journal of Medicine, which showed ghrelin remained elevated one year after a 10-week very-low-calorie diet. [7]

For longevity-oriented clinical practice, the HealthRX medical team uses the following interpretive framework:

• Fasting acyl ghrelin <50 pg/mL: consistent with metabolic health and adequate adiposity signaling
• Fasting acyl ghrelin 50 to 80 pg/mL: borderline; assess cycle phase, testosterone, sleep quality, and stress cortisol
• Fasting acyl ghrelin >80 pg/mL: clinically elevated; evaluate for weight-regain risk, sleep apnea (which independently raises ghrelin), and poor dietary protein intake

This framework does not constitute a diagnostic criterion. It is a clinical decision-support guide pending more prospective outcome data in optimized-health populations.

Ghrelin and GLP-1 Receptor Agonists: The Appetite-Suppression Overlap

GLP-1 receptor agonists (GLP-1 RAs) like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) suppress appetite through multiple pathways. Ghrelin suppression is one of them, though the magnitude is smaller than their effects on gastric emptying and central satiety signaling.

What the Clinical Trials Show

In a substudy of the SCALE Obesity trial, liraglutide 3.0 mg daily reduced post-meal ghrelin area under the curve (AUC) compared with placebo over 56 weeks. [8] Semaglutide data from the STEP-1 trial (N=1,961) showed 14.9% mean body weight loss at 68 weeks versus 2.4% placebo. [9] While STEP-1 did not specifically report ghrelin endpoints, smaller mechanistic studies confirm that semaglutide blunts the post-meal ghrelin rebound that normally signals hunger within 90 to 120 minutes of eating.

Sex-Specific Responses to GLP-1 Plus Ghrelin

Women starting semaglutide tend to enter treatment with higher baseline ghrelin than men of comparable BMI. Whether this translates into a larger absolute ghrelin suppression on GLP-1 therapy is an active research question. A 2022 mechanistic analysis by Ard et al. Noted that women in STEP-1 lost modestly more weight as a percentage of body weight than men (15.8% vs. 13.1%), and ghrelin dynamics may contribute to that difference, though the trial was not powered to isolate that mechanism. [10]

Practical Monitoring Point

When monitoring patients on GLP-1 RA therapy who report plateau or hunger rebound after dose increase, drawing fasting acyl ghrelin can quantify whether ghrelin suppression has been achieved. A persistently elevated post-meal ghrelin rebound may indicate that the dose has not reached adequate receptor saturation for that individual's physiology.

Testosterone, TRT, and Ghrelin in Men

Low testosterone and high ghrelin co-exist more often than chance would predict. Both conditions correlate with visceral adiposity, insulin resistance, and poor sleep, which makes causal direction hard to establish from cross-sectional data alone. The Pagotto et al. Intervention study [2] and a later 2013 trial by Grossmann et al. (N=88) in obese men with type 2 diabetes on testosterone undecanoate 1,000 mg IM every 12 weeks provide some directional evidence. [11]

Mechanism: How Testosterone Suppresses Ghrelin

Androgen receptors are expressed on gastric X/A-like cells. Testosterone binding reduces preproghrelin gene transcription, lowering both acyl and des-acyl ghrelin output. This is distinct from the indirect suppression that occurs when testosterone reduces visceral fat (which independently lowers ghrelin). Even in lean hypogonadal men with normal BMI, ghrelin runs higher, suggesting a direct gonadal mechanism. [2]

TRT Monitoring Protocol

Men starting TRT (typically testosterone cypionate 100 to 200 mg/week IM or SC, or testosterone undecanoate 750 mg IM per AVEED prescribing information) should have fasting acyl ghrelin drawn at baseline and repeated at 12 weeks. A failure to suppress ghrelin by at least 15 to 20% at 12 weeks despite achieving testosterone levels above 500 ng/dL should prompt evaluation for other ghrelin-elevating conditions: sleep apnea, high cortisol, or very low dietary protein intake.

Ghrelin in Pregnancy

Ghrelin follows a paradoxical pattern during pregnancy. Despite the major weight gain and rising adiposity that normally suppress ghrelin, total ghrelin falls across all three trimesters, reaching its nadir in the third trimester, then rebounding sharply in the postpartum period. [12] This suppression is thought to be placenta-mediated, possibly through human chorionic gonadotropin (hCG) and placental lactogen.

The postpartum ghrelin rebound may contribute to the increased appetite many women report in the weeks after delivery, particularly those who are not breastfeeding. Breastfeeding appears to attenuate the ghrelin rebound modestly, though data are limited to small observational cohorts. [12]

Pre-Analytical Pitfalls: Why Ghrelin Results Are Often Wrong

Ghrelin is one of the most technically demanding hormones to measure accurately. Several pre-analytical errors can render results uninterpretable.

Sample Collection Requirements

Acyl ghrelin degrades to des-acyl ghrelin within 30 minutes at room temperature through enzymatic deacylation. Samples must be collected into tubes containing EDTA and a serine protease inhibitor (typically 4-aminomethylbenzenesulfonyl fluoride, AEBSF). They must be centrifuged and frozen within 30 minutes of draw. Labs not using this protocol will underreport acyl ghrelin substantially.

Fasting Requirement

Ghrelin is pulsatile and meal-suppressed. Draw must occur after a minimum 8-hour fast. A result obtained 2 hours post-meal could be 30 to 50% lower than a true fasting value. [6]

BMI Confounding

Ghrelin is inversely correlated with BMI across all sex and age groups. A woman with a BMI of 35 may have an acyl ghrelin of 20 pg/mL that appears "low-normal" but is actually appropriate for her adiposity. Interpreting ghrelin without noting BMI leads to systematic misclassification.

How to Order and Interpret Ghrelin in Clinical Practice

Ordering ghrelin as a stand-alone test without clinical context produces noise, not signal. The following framework applies to patients in weight management, TRT, HRT, or GLP-1 programs.

Recommended Co-Tests

Draw ghrelin alongside:

• Fasting insulin and glucose (calculate HOMA-IR)
• Testosterone (total and free) in men; estradiol and FSH in women
• Cortisol (AM, fasting)
• Leptin (ghrelin and leptin together define the hunger-satiety axis)
• TSH (hypothyroidism independently raises ghrelin)

Timing for Women

Document LMP and cycle day at draw. Request acyl ghrelin specifically; confirm the lab uses EDTA-protease-inhibitor tubes. Draw in the early follicular phase (days 2 to 5) for the most reproducible baseline, since this avoids both the ovulatory nadir and the progesterone-modified luteal rise.

Interpreting Elevated Results

Elevated fasting acyl ghrelin (>70 pg/mL in a non-obese adult) in the context of weight-loss resistance, persistent hunger, or sleep disturbance should trigger:

1. Polysomnography referral (sleep apnea raises ghrelin independently of BMI)
2. Cortisol assessment (chronic stress drives ghrelin via CRH)
3. Dietary protein audit (protein is the strongest macronutrient suppressor of ghrelin, reducing fasting levels by up to 33% at intakes above 25% of total calories per a trial by Blom et al.) [13]
4. Review of current GLP-1 dose or consider initiation if criteria are met per FDA labeling

The American Association of Clinical Endocrinology 2022 Obesity Guidelines state: "Ghrelin and other appetite-regulating hormones should be considered as part of a comprehensive metabolic evaluation in patients with obesity and treatment resistance." [14]